BETA: Please send your feedback!
TG Therapeutics
TGTX:NAS
Biotechnology
$0
SMALL cap
$10.33
(0.23%)
-0.07%
since start of 2020
-5.28
About
Biotechnology
Founded 1993
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| H. Laurence Shaw, MD | Founder | Male |
| Michael Sean Weiss | Executive Chairman, President & CEO | Male |
| Jenna A. Bosco | Vice President-Investor Relations | Female |
| Sean A. Power, CPA | Chief Financial Officer, Secretary & Treasurer | Male |
| Robert Niecestro, PhD | Executive Vice President-Clinical & Regulatory | Male |
Mindful Investing Summary
TG Therapeutics - Competitors and Related Companies
How TG Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
TG Therapeutics
TGTX:NAS
Biotechnology
$0
SMALL cap
$10.33
(0.23%)
-0.07%
since start of 2020
-5.28
ImmunoGen
IMGN:NAS
Biotechnology
$607.51mm
SMALL cap
$3.48
(-0.01%)
-0.33%
since start of 2020
-4.95
Dr. Reddy's Laboratories
500124-IN:BOM
Pharmaceuticals: Generic
—
MID cap
(—)
—
since start of 2020
—
Histogenics
HSGX:NAS
Biotechnology
$15.33mm
MICRO cap
$0.16
(-0.07%)
0.01%
since start of 2020
0.84
Navidea Biopharmaceuticals
NAVB:ASE
Biotechnology
—
MICRO cap
$0.78
(—)
—
since start of 2020
—